Photo taken from doctors.columbia.edu
May 24, 2024, 14:22
Ryan Moy: Our investigator-initiated trial for diffuse gastric cancer after progression on first-line therapy is now open at Columbia!
Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center, made the following post on X:
“Our investigator-initiated trial targeting the FAK and MAPK pathways with defactinib and avutometinib for patients with diffuse gastric cancer after progression on first-line therapy is now open at Columbia!”
Read the article.
Source: Ryan Moy/X
.
Assistant Professor of Medicine
avutometinib
cancer
Cancer research
clinical trial
Columbia University Irving Medical Center
defactinib
diffuse gastric cancer
FAK pathway
first-line therapy
Healthcare Innovation
investigator-initiated trial
MAPK pathway
medical oncology
OncoDaily
Oncology
Research
Ryan Moy